Approaches to target profiling of natural products

Current Medicinal Chemistry

Volumn 19, Issue 22, 2012, Pages 3841-3855

  Yue, R ^a   Shan, L ^a   Yang, X ^a   Zhang, W ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Affinity chromatography; Chemobioinformatics; Genomics; Mechanism of action; Molecular docking; Natural products; Pharmacophore; Proteomics; System biological network analysis; Target profiling

Indexed keywords

[6] GINGEROL; ANTINEOPLASTIC AGENT; APRATOXIN A; AURILIDE; AVRAINVILLAMIDE; DIOSCIN; EUXANTHONE; GANODERIC ACID D; HERBOXIDIENE; HIPPURISTANOL; LEUCASCANDROLIDE A; NATURAL PRODUCT; NEOPELTOLIDE; PAEONIFLORIN; PLADIENOLIDE B; PROTEOME; PSYMBERIN; RESVERATROL; S GAMBOGIC ACID; SESTERTERPENE; SPLICEOSTATIN A; SUDEMYCIN C; SYRINGOLIN A; TACROLIMUS; THEONELLAMIDE; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

AFFINITY CHROMATOGRAPHY; ANTINEOPLASTIC ACTIVITY; BIOINFORMATICS; BIOLOGICAL ACTIVITY; BIOLOGY; DNA MICROARRAY; DRUG DESIGN; GENETIC PROCEDURES; GENOMICS; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICAL RESEARCH; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHAGE DISPLAY; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; STRUCTURE ANALYSIS; SYSTEMS BIOLOGY; THREE HYBRID SYSTEM; TWO DIMENSIONAL ELECTROPHORESIS; YEAST;

BIOLOGICAL AGENTS; COMPUTATIONAL BIOLOGY; DRUG EVALUATION, PRECLINICAL; GENOMICS; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEOMICS;

EID: 84865249165     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801661068     Document Type: Review

References (174)

1. Shukla S. K.; Gupta S.; Ojha S. K.; Sharma S. B. Cardiovascular friendly natural products: a promising approach in the management of CVD. Nat. Prod. Res., 2010, 24, 873-98.
2. Gordaliza M. Natural products as leads to anticancer drugs. Clin. Transl. Oncol., 2007, 9, 767-76.
3. Bailly C. Ready for a comeback of natural products in oncology. Biochem. Pharmacol., 2009, 77, 1447-57.
4. Demain A. L. Antibiotics: Natural products essential to human health. Med. Res. Rev., 2009, 29, 821-42.
5. Cragg G. M.; Newman D. J. Biodiversity: A continuing source of novel drug leads. Pure Appl. Chem., 2005, 77, 7-24. (Pubitemid 40321875)
6. Butler M. S. Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep., 2008, 25, 475-516. (Pubitemid 351725315)
7. Qi Y.; Ma S. The Medicinal Potential of Promising Marine Macrolides with Anticancer Activity. ChemMedChem, 2011, 6, 399-409.
8. Kinghorn A. D.; Chin Y. W.; Swanson S. M. Discovery of natural product anticancer agents from biodiverse organisms. Curr. Opin. Drug Disc., 2009, 12, 189-96.
9. Molinski T. F.; Dalisay D. S.; Lievens S. L.; Saludes J. P. Drug development from marine natural products. Nat. Rev. Drug Discov., 2008, 8, 69-85.
10. Cragg G. M.; Grothaus P. G.; Newman D. J. Impact of Natural Products on Developing New Anti-Cancer Agents. Chem. Rev., 2009, 109, 3012-43.
11. Newman D. J.; Cragg G. M. Natural Products as Sources of New Drugs over the Last 25 Years. J.Nat. Prod., 2007, 70, 461-77. (Pubitemid 46595760)
12. Harvey A. L. Natural products in drug discovery. Drug Discovery Today, 2008, 13, 894-901.
13. Ganesan A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol., 2008, 12, 306-17.
14. Ji H. F.; Li X. J.; Zhang H. Y. Natural products and drug discovery. EMBO Rep., 2009, 10, 194-200.
15. Schneider G.; Baringhaus K. Molecular Design-creating the Design: WILLEY-VCH Verlag GmbH & Co. KGaA, Weinheim: Germany, 2008.
16. Carlson E. E. Natural products as chemical probes. ACS Chem. Biol., 2010, 5, 639-53.
17. Marton M. J.; DeRisi J. L.; Bennett H. A.; Iyer V. R.; Meyer M. R.; Roberts C. J.; Stoughton R.; Burchard J.; Slade D.; Dai H. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med., 1998, 4, 1293-301. (Pubitemid 28512111)
18. Lindsay M. A. Target discovery. Nat. Rev. Drug Discov., 2003, 2, 831-38. (Pubitemid 37361815)
19. Orth A. P.; Batalov S.; Perrone M.; Chanda S. K. The promise of genomics to identify novel therapeutic targets. Expert Opin. Ther. Tar., 2004, 8, 587-96. (Pubitemid 40028368)
20. Garcia-Lara J.; Masalha M.; Foster S. J. Staphylococcus aureus: the search for novel targets. Drug Discov. Today, 2005, 10, 643-51. (Pubitemid 40704772)
21. Gresham V.; McLeod H. L. Genomics: Applications in mechanism elucidation. Adv. Drug Delver. Rev., 2009, 61, 369-74.
22. Luesch H.; Chanda S. K.; Raya R. M.; DeJesus P. D.; Orth A. P.; Walker J. R.; Belmonte J. C. I.; Schultz P. G. A functional genomics approach to the mode of action of apratoxin A. Nat. Chem. Biol., 2006, 2, 158-67. (Pubitemid 44323868)
23. Bredel M.; Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet., 2004, 5, 262-75. (Pubitemid 38435622)
24. Kawasumi M.; Nghiem P. Chemical genetics: elucidating biological systems with small-molecule compounds. J. Invest. Dermatol., 2007, 127, 1577-84. (Pubitemid 46933419)
25. Gaither L. A. Chemogenomics approaches to novel target discovery. Expert Rev. Proteomic, 2007, 4, 411-19. (Pubitemid 46890078)
26. Ahn Y. H.; Chang Y. T. Tagged small molecule library approach for facilitated chemical genetics. Acc. Chem. Res., 2007, 40, 1025-33.
27. Zheng X. S.; Chan T. F.; Zhou H. H. Genetic and genomic approaches to identify and study the targets of bioactive small molecules. Chem. Biol., 2004, 11, 609-18. (Pubitemid 38708830)
28. Hoon S.; Smith A. M.; Wallace I. M.; Suresh S.; Miranda M.; Fung E.; Proctor M.; Shokat K. M.; Zhang C.; Davis R. W. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat. Chem. Biol., 2008, 4, 498-506.
29. Lamb J.; Crawford E. D.; Peck D.; Modell J. W.; Blat I. C.; Wrobel M. J.; Lerner J.; Brunet J. P.; Subramanian A.; Ross K. N. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006, 313, 1929-35. (Pubitemid 44497995)
30. Iorio F.; Tagliaferri R.; Bernardo D. Identifying network of drug mode of action by gene expression profiling. J. Comput. Biol., 2009, 16, 241-51.
31. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer, 2007, 7, 54-60. (Pubitemid 46020847)
32. Bordeleau M. E.; Mori A.; Oberer M.; Lindqvist L.; Chard L. S.; Higa T.; Belsham G. J.; Wagner G.; Tanaka J.; Pelletier J. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol., 2006, 2, 213-20.
33. Fisch K. M.; Gurgui C.; Heycke N.; van der Sar S. A.; Anderson S. A.; Webb V. L.; Taudien S.; Platzer M.; Rubio B. K.; Robinson S. J. Polyketide assembly lines of uncultivated sponge symbionts from structure-based gene targeting. Nat. Chem. Biol., 2009, 5, 494-501.
34. Nishimura S.; Arita Y.; Honda M.; Iwamoto K.; Matsuyama A.; Shirai A.; Kawasaki H.; Kakeya H.; Kobayashi T.; Matsunaga S. Marine antifungal theonellamides target 3β-hydroxysterol to activate Rho1 signaling. Nat. Chem. Biol., 2010, 6:, 516-26.
35. Wright A. E.; Botelho J. C.; Guzmán E.; Harmody D.; Linley P.; McCarthy P. J.; Pitts T. P.; Pomponi S. A.; Reed J. K. Neopeltolide, a Macrolide from a Lithistid Sponge of the Family Neopeltidae. J. Nat. Prod., 2007, 70, 412-16. (Pubitemid 46595749)
36. Ulanovskaya O. A.; Janjic J.; Suzuki M.; Sabharwal S. S.; Schumacker P. T.; Kron S. J.; Kozmin S. A. Synthesis enables identification of the cellular target of leucascandrolide A and neopeltolide. Nat. Chem. Biol., 2008, 4, 418-24. (Pubitemid 351860551)
37. Altmann K. H.; Carreira E. M. Unraveling a molecular target of macrolides. Nat. Chem. Biol., 2008, 4, 388-89. (Pubitemid 351863595)
38. Peddibhotla S.; Dang Y.; Liu J. O.; Romo D. Simultaneous arming and structure/activity studies of natural products employing OH insertions: An expedient and versatile strategy for natural products-based chemical genetics. J. Am. Chem. Soc., 2007, 129, 12222-31. (Pubitemid 47556858)
39. Veenstra T. D. Proteomic approaches in drug discovery. Drug Discov. Today, 2007, 3, 433-40. (Pubitemid 46158386)
40. Mallick P.; Kuster B. Proteomics: a pragmatic perspective. Nat. Biotechnol., 2010, 28, 695-709.
41. Sleno L.; Emili A. Proteomic methods for drug target discovery. Curr. Opin. Chem. Biol., 2008, 12, 46-54.
42. Timms J. F.; Cramer R. Difference gel electrophoresis. Proteomics, 2008, 8, 4886-97.
43. Ha W.; Wu P.; Kok T.; Leung K.; Mak N.; Yue P.; Ngai S.; Tsai S.; Wong R. Involvement of protein kinase C and E2F-5 in euxanthone-induced neurite differentiation of neuroblastoma. Int. J. Biochem. Cell Biol., 2006, 38, 1393-401.
44. Chen D.; Xiao L.; Cai X.; Zeng R.; Zhu X. Involvement of multitargets in paeoniflorin-induced preconditioning. J. Pharmacol. Exp. Ther., 2006, 319, 165-80. (Pubitemid 44455121)
45. Wang Y.; Cheung Y.; Yang Z.; Chiu J.; Che C.; He Q. Proteomic approach to study the cytotoxicity of dioscin (saponin). Proteomics, 2006, 6, 2422-32.
46. Wang Y.; Che C.; Chiu J.; He Q. Dioscin (Saponin)-Induced Generation of Reactive Oxygen Species through Mitochondria Dysfunction: A Proteomic-Based Study. J. Proteome Res., 2007, 6, 4703-10.
47. Yue Q.; Cao Z.; Guan S.; Liu X.; Tao L.; Wu W.; Li Y.; Yang P.; Liu X.; Guo D. Proteomics characterization of the cytotoxicity mechanism of ganoderic acid D and computer-automated estimation of the possible drug target network. Mol. Cell. Proteomics, 2008, 7, 949-61. (Pubitemid 351737094)
48. Wang X.; Chen Y.; Han Q.; Chan C.; Wang H.; Liu Z.; Cheng C.; Yew D.; Lin M.; He M. Proteomic identification of molecular targets of gambogic acid: Role of stathmin in hepatocellular carcinoma. Proteomics, 2009, 9, 242-53.
49. Bantscheff M.; Schirle M.; Sweetman G.; Rick J.; Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem., 2007, 389, 1017-31. (Pubitemid 47482251)
50. Rix U.; Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol., 2008, 5, 616-24.
51. Harsha H.; Molina H.; Pandey A. Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat. Protoc., 2008, 3, 505-16. (Pubitemid 351372235)
52. Gygil S. P.; Rist B.; Gerber S. A.; Turecek F.; Gelb M. H.; Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol., 1999, 17, 994-99. (Pubitemid 29474856)
53. Wiese S.; Reidegeld K. A.; Meyer H. E.; Warscheid B. Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics, 2007, 7, 340-50. (Pubitemid 46293976)
54. Bantscheff M.; Eberhard D.; Abraham Y.; Bastuck S.; Boesche M.; Hobson S.; Mathieson T.; Perrin J.; Raida M.; Rau C. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol., 2007, 25, 1035-44. (Pubitemid 47517638)
55. Wang C.; Zhou J.; Wang S.; Ye M.; Jiang C.; Fan G.; Zou H. Combined comparative and chemical proteomics on the mechanisms of levotetrahydropalmatine-induced antinociception in the formalin test. J. Proteome Res., 2010, 9, 3225-34.
56. Ong S. E.; Schenone M.; Margolin A. A.; Li X.; Do K.; Doud M. K.; Mani D.; Kuai L.; Wang X.; Wood J. L. Identifying the proteins to which smallmolecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 4617-22.
57. Hu L.; Xu S.; Pan C.; Zou H.; Jiang G. Preparation of a biochip on porous silicon and application for label-free detection of small molecule-protein interactions. Rapid Commun. Mass Spectrom., 2007, 21, 1277-81. (Pubitemid 46506582)
58. Zhu H.; Snyder M. Protein chip technology. Curr. Opin. Chem. Biol., 2003, 7, 55-63. (Pubitemid 36126493)
59. Huang J.; Zhu H.; Haggarty S. J.; Spring D. R.; Hwang H.; Jin F.; Snyder M.; Schreiber S. L. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 16594-99. (Pubitemid 39557758)
60. Licitra E. J.; Liu J. O. A three-hybrid system for detecting small ligand-protein receptor interactions. Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 12817-21. (Pubitemid 26382726)
61. Becker F.; Murthi K.; Smith C.; Come J.; Costa-Roldán N.; Kaufmann C.; Hanke U.; Degenhart C.; Baumann S.; Wallner W. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem. Biol., 2004, 11, 211-23. (Pubitemid 38300291)
62. Licitra E. J.; Liu J. O. A three-hybrid system for detecting small ligand-protein receptor interactions. Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 12817-21. (Pubitemid 26382726)
63. Shim J. S.; Lee J.; Park H. J.; Park S. J.; Kwon H. J. A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. Chem. Biol., 2004, 11, 1455-63. (Pubitemid 39351381)
64. Formosa T.; Barry J.; Alberts B.; Greenblatt J. Using protein affinity chromatography to probe structure of protein machines. Methods Enzymol., 1991, 208, 24-45.
65. Saxena C.; Higgs R. E.; Zhen E.; Hale J. E. Small-molecule affinity chromatography coupled mass spectrometry for drug target deconvolution. Expert Opin. Drug Dis., 2009, 4, 701-14.
66. Leslie B. J.; Hergenrother P. J. Identification of the cellular targets of bioactive small organic molecules using affinity reagents. Chem. Soc. Rev., 2008, 37, 1347-60.
67. Cheng K. W.; Wong C. C.; Wang M.; He Q. Y.; Chen F. Identification and characterization of molecular targets of natural products by mass spectrometry. Mass Spectrom. Rev., 2010, 29, 126-55.
68. Bttcher T.; Pitscheider M.; Sieber S. A. Natural products and their biological targets: proteomic and metabolomic labeling strategies. Angew. Chem. Int. Ed., 2010, 49, 2680-98.
69. Terstappen G.; Schlüpen C.; Raggiaschi R.; Gaviraghi G. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Disc., 2007, 6, 891-903. (Pubitemid 350042397)
70. Vegas A. J.; Fuller J. H.; Koehler A. N. Small-molecule microarrays as tools in ligand discovery. Chem. Soc. Rev., 2008, 37, 1385-94.
71. Bach S.; Knockaert M.; Reinhardt J.; Lozach O.; Schmitt S.; Baratte B.; Koken M.; Coburn S.; Tang L.; Jiang T. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem., 2005, 280, 31208-19. (Pubitemid 41291858)
72. Zhang Q.; Major M.; Takanashi S.; Camp N.; Nishiya N.; Peters E.; Ginsberg M.; Jian X.; Randazzo P.; Schultz P. Small-molecule synergist of the Wnt/β-catenin signaling pathway. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 7444-48. (Pubitemid 47185925)
73. Makoto K.; Hideo O.; Kaori H.; Naoki Kanoh; Makoto Muroi; Naoshi Dohmae; Masamichi Takami; Mitsuhiro Kitagawa; Yushi Futamura; Masaya Imoto; Osada H. The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 11691-96.
74. Snyder J.; Hall A.; Ni-Komatsu L.; Khersonsky S.; Chang Y.; Orlow S. Dissection of melanogenesis with small molecules identifies prohibitin as a regulator. Chem. Biol., 2005, 12, 477-84. (Pubitemid 40588923)
75. Oda Y.; Owa T.; Sato T.; Boucher B.; Daniels S.; Yamanaka H.; Shinohara Y.; Yokoi A.; Kuromitsu J.; Nagasu T. Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem, 2003, 75, 2159-65. (Pubitemid 36542358)
76. Wang G.; Shang L.; Burgett A.; Harran P.; Wang X. Diazonamide toxins reveal an unexpected function for ornithine δ-amino transferase in mitotic cell division. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 2068-73. (Pubitemid 46391353)
77. Sato S.; Kwon Y.; Kamisuki S.; Srivastava N.; Mao Q.; Kawazoe Y.; Uesugi M. Polyproline-Rod Approach to Isolating Protein Targets of Bioactive Small Molecules: Isolation of a New Target of Indomethacin. J. Am. Chem. Soc., 2007, 129, 873-80. (Pubitemid 46188236)
78. Emami K.; Nguyen C.; Ma H.; Kim D.; Jeong K.; Eguchi M.; Moon R.; Teo J.; Oh S.; Kim H. A small molecule inhibitor of β-catenin/CREB-binding protein transcription. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 12682-87.
79. Yamamoto K.; Yamazaki A.; Takeuchi M.; Tanaka A. A versatile method of identifying specific binding proteins on affinity resins. Anal. Biochem., 2006, 352, 15-23.
80. Wulff J. E.; Siegrist R.; Myers A. G. The natural product avrainvillamide binds to the oncoprotein nucleophosmin. J. Am. Chem. Soc., 2007, 129, 14444-51. (Pubitemid 350171471)
81. Dal Piaz F.; Vassallo A.; Lepore L.; Tosco A.; Bader A.; De Tommasi N. Sesterterpenes as Tubulin Tyrosine Ligase Inhibitors. First Insight of Structure Activity Relationships and Discovery of New Lead. J. Med. Chem., 2009, 52, 327-29.
82. Clerc J.; Florea B. I.; Kraus M.; Groll M.; Huber R.; Bachmann A. S.; Dudler R.; Driessen C.; Overkleeft H. S.; Kaiser M. Syringolin A Selectively Labels the 20 S Proteasome in Murine EL4 and Wild-Type and Bortezomib-Adapted Leukaemic Cell Lines. ChemBioChem, 2009, 10, 2638-43.
83. Lomenick B.; Hao R.; Jonai N.; Chin R. M.; Aghajan M.; Warburton S.; Wang J.; Wu R. P.; Gomez F.; Loo J. A. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 21984-89.
84. Suenaga K.; Kajiwara S.; Kuribayashi S.; Handa T.; Kigoshi H. Synthesis and cytotoxicity of aurilide analogs. Bioorg. Med. Chem. Lett., 2008, 18, 3902-05.
85. Sievers C.; Billig G.; Gottschalk K.; Rudel T.; Aziz S. A. Prohibitins are required for cancer cell proliferation and adhesion. PLoS One, 2010, 5, e12735.
86. Merkwirth C.; Dargazanli S.; Tatsuta T.; Geimer S.; Lwer B.; Wunderlich F. T.; von Kleist-Retzow J. C.; Waisman A.; Westermann B.; Langer T. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev., 2008, 22, 476-88. (Pubitemid 351272755)
87. Sato S.; Murata A.; Orihara T.; Shirakawa T.; Suenaga K.; Kigoshi H.; Uesugi M. Marine Natural Product Aurilide Activates the OPA1-Mediated Apoptosis by Binding to Prohibitin. Chem. Biol., 2011, 18, 131-39.
88. Semenzato M.; Cogliati S.; Scorrano L. Prohibitin (g) Cancer: Aurilide and Killing by Opa1-Dependent Cristae Remodeling. Chem. Biol., 2011, 18, 8-9.
89. Costa V.; Giacomello M.; Hudec R.; Lopreiato R.; Ermak G.; Lim D.; Malorni W.; Davies K. J. A.; Carafoli E.; Scorrano L. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol. Med., 2010, 2:, 490-503.
90. Wang J. X.; Jiao J. Q.; Li Q.; Long B.; Wang K.; Liu J. P.; Li Y. R.; Li P. F. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat. Med., 2010, 17, 71-78.
91. Adam G.; Sorensen E.; Cravatt B. Chemical Strategies for Functional Proteomics. Mol. Cell. Proteomics, 2002, 1, 781-90.
92. Cravatt B.; Wright A.; Kozarich J. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem., 2008, 77, 383-414.
93. Jessani N.; Cravatt B. The development and application of methods for activity-based protein profiling. Curr. Opin. Chem. Biol., 2004, 8, 54-59. (Pubitemid 38201478)
94. Speers A.; Cravatt B. Chemical strategies for activity-based proteomics. ChemBioChem, 2004, 5, 41-47. (Pubitemid 38095018)
95. Sadaghiani A. M.; Verhelst S. H. L.; Bogyo M. Tagging and detection strategies for activity-based proteomics. Curr. Opin. Chem. Biol., 2007, 11, 20-28. (Pubitemid 46216128)
96. Peters E. C.; Gray N. S. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors. ACS Chem. Biol., 2007, 2, 661-64. (Pubitemid 350066014)
97. Li W.; Blankman J. L.; Cravatt B. F. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J. Am. Chem. Soc., 2007, 129, 9594-95. (Pubitemid 47237463)
98. Duncan J.; Gyenis L.; Lenehan J.; Bretner M.; Graves L.; Haystead T.; Litchfield D. An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics: Characterization of Inhibitor Effects on CK2 and Identification of Novel Inhibitor Targets. Mol. Cell. Proteomics, 2008, 7, 1077-88. (Pubitemid 351943955)
99. Greenbaum D.; Baruch A.; Hayrapetian L.; Darula Z.; Burlingame A.; Medzihradszky K.; Bogyo M. Chemical Approaches for Functionally Probing the Proteome. Mol. Cell. Proteomics, 2002, 1, 60-68.
100. Kato D.; Boatright K.; Berger A.; Nazif T.; Blum G.; Ryan C.; Chehade K.; Salvesen G.; Bogyo M. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol., 2005, 1, 33-38.
101. Blum G.; Mullins S.; Keren K.; Fonovič M.; Jedeszko C.; Rice M.; Sloane B.; Bogyo M. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol., 2005, 1, 203-09.
102. Hemelaar J.; Borodovsky A.; Kessler B.; Reverter D.; Cook J.; Kolli N.; Gan-Erdene T.; Wilkinson K.; Gill G.; Lima C. Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol. Cell. Biol., 2004, 24, 84-95. (Pubitemid 38010037)
103. Hemelaar J.; Galardy P.; Borodovsky A.; Kessler B.; Ploegh H.; Ovaa H. Chemistry-based functional proteomics: mechanism-based activity-profiling tools for ubiquitin and ubiquitin-like specific proteases. J. Proteome Res., 2004, 3, 268-76. (Pubitemid 38500994)
104. Borodovsky A.; Ovaa H.; Meester W.; Venanzi E.; Bogyo M.; Hekking B.; Ploegh H.; Kessler B.; Overkleeft H. Small-molecule inhibitors and probes for ubiquitin-and ubiquitin-like-specific proteases. ChemBioChem, 2005, 6, 287-90.
105. Bachovchin D. A.; Brown S. J.; Rosen H.; Cravatt B. F. Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes. Nat. Biotechnol., 2009, 27, 387-94.
106. Griffith E. C.; Su Z.; Turk B. E.; Chen S.; Chang Y. H.; Wu Z.; Biemann K.; Liu J. O. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol., 1997, 4, 461-71. (Pubitemid 27288711)
107. Chen J. K.; Lane W. S.; Schreiber S. L. The identification of myriocinbinding proteins. Chem. Biol., 1999, 6, 221-35.
108. Adam G. C.; Vanderwal C. D.; Sorensen E. J.; Cravatt B. F. (-)-FR182877 Is a Potent and Selective Inhibitor of Carboxylesterase-1. Angew. Chem. Int. Ed., 2003, 115, 5638-42.
109. Piggott A. M.; Karuso P. Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery. Comb. Chem. High T. Scr., 2004, 7, 607-30. (Pubitemid 39371210)
110. Piggott A. M.; Karuso P. Quality not quantity: the role of marine natural products in drug discovery and reverse chemical proteomics. Mar. Drugs, 2005, 3, 36-63. (Pubitemid 41056618)
111. Lenz T.; Fischer J. J.; Dreger M. Probing small molecule-protein interactions: A new perspective for functional proteomics. J. Proteomics, 2011, 75, 100-15.
112. Luo Y.; Blex C.; Baessler O.; Glinski M.; Dreger M.; Sefkow M.; Köster H. The cAMP Capture Compound Mass Spectrometry as a Novel Tool for Targeting cAMP-binding Proteins. Mol. Cell. Proteomics, 2009, 8, 2843-56.
113. Fischer J. J.; Michaelis S.; Schrey A. K.; Glinski M.; Dreger M.; Kroll F.; Koester H. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs. Toxicol. Sci., 2010, 113, 243-53.
114. Northcote P. T.; Blunt J. W.; Munro M. H. G. Pateamine: a potent cytotoxin from the New Zealand marine sponge, Mycale Sp. Tetrahedron Lett., 1991, 32, 6411-14.
115. Low W. K.; Dang Y.; Schneider-Poetsch T.; Shi Z.; Choi N. S.; Merrick W. C.; Romo D.; Liu J. O. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol. Cell, 2005, 20, 709-22. (Pubitemid 41740693)
116. Bordeleau M. E.; Matthews J.; Wojnar J. M.; Lindqvist L.; Novac O.; Jankowsky E.; Sonenberg N.; Northcote P.; Teesdale-Spittle P.; Pelletier J. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 10460-65. (Pubitemid 41061576)
117. Bordeleau M. E.; Cencic R.; Lindqvist L.; Oberer M.; Northcote P.; Wagner G.; Pelletier J. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem. Biol., 2006, 13, 1287-95. (Pubitemid 44932234)
118. Low W. K.; Dang Y.; Bhat S.; Romo D.; Liu J. O. Substrate-dependent targeting of eukaryotic translation initiation factor 4A by pateamine A: negation of domain-linker regulation of activity. Chem. Biol., 2007, 14, 715-27. (Pubitemid 46920988)
119. Dang Y.; Low W. K.; Xu J.; Gehring N. H.; Dietz H. C.; Romo D.; Liu J. O. Inhibition of nonsense-mediated mRNA decay by the natural product pateamine A through eukaryotic initiation factor 4AIII. J. Biol. Chem., 2009, 284, 23613-21.
120. Kuznetsov G.; Xu Q.; Rudolph-Owen L.; TenDyke K.; Liu J.; Towle M.; Zhao N.; Marsh J.; Agoulnik S.; Twine N. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol. Cancer Ther., 2009, 8, 1250-60.
121. Kotake Y.; Sagane K.; Owa T.; Mimori-Kiyosue Y.; Shimizu H.; Uesugi M.; Ishihama Y.; Iwata M.; Mizui Y. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol., 2007, 3, 570-75. (Pubitemid 47294394)
122. Kaida D.; Motoyoshi H.; Tashiro E.; Nojima T.; Hagiwara M.; Ishigami K.; Watanabe H.; Kitahara T.; Yoshida T.; Nakajima H. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol., 2007, 3, 576-83. (Pubitemid 47294395)
123. Hasegawa M.; Miura T.; Kuzuya K.; Inoue A.; Ki S. W.; Horinouchi S.; Yoshida T.; Kunoh T.; Koseki K.; Mino K. Identification of SAP155 as the Target of GEX1A (Herboxidiene), An Antitumor Natural Product. ACS Chem. Biol., 2011, 6:, 229-33.
124. Fan L.; LAGISETTI C.; Edwards C. C.; Webb T. R.; Potter P. M. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem. Biol., 2011, 6, 582-89.
125. Van Alphen R.; Wiemer E.; Burger H.; Eskens F. The spliceosome as target for anticancer treatment. Br. J. Cancer, 2008, 100, 228-32.
126. Mestres J. Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr. Opin. Drug Disc., 2004, 7, 304-13. (Pubitemid 44120947)
127. Keiser M. J.; Roth B. L.; Armbruster B. N.; Ernsberger P.; Irwin J. J.; Shoichet B. K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 2007, 25, 197-206. (Pubitemid 46227119)
128. Rollinger J.; Langer T.; Stuppner H. Integrated in Silico Tools for Exploiting the Natural Product's Bioactivity. Planta Med., 2006, 72, 671-78. (Pubitemid 44073448)
129. Li H.; Li C.; Gui C.; Luo X.; Chen K.; Shen J.; Wang X.; Jiang H. GAsDock: a new approach for rapid flexible docking based on an improved multipopulation genetic algorithm. Bioorg. Med. Chem. Lett., 2004, 14, 4671-76. (Pubitemid 39490287)
130. Gao Z.; Li H.; Zhang H.; Liu X.; Kang L.; Luo X.; Zhu W.; Chen K.; Wang X.; Jiang H. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008, 9, 104.
131. Liu X.; Ouyang S.; Yu B.; Liu Y.; Huang K.; Gong J.; Zheng S.; Li Z.; Li H.; Jiang H. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res., 2010, 38, W609-W14.
132. Li H.; Gao Z.; Kang L.; Zhang H.; Yang K.; Yu K.; Luo X.; Zhu W.; Chen K.; Shen J. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res., 2006, 34, W219-24. (Pubitemid 44529767)
133. Zhang S.; Lu W.; Liu X.; Diao Y.; Bai F.; Wang L.; Shan L.; Huang J.; Li H.; Zhang W. Fast and effective identification of the bioactive compounds and their targets from medicinal plants via computational chemical biology approach. Med. Chem. Commun., 2011, 2, 471-77.
134. Jeong C. H.; Bode A. M.; Pugliese A.; Cho Y. Y.; Kim H. G.; Shim J. H.; Jeon Y. J.; Li H.; Jiang H.; Dong Z. [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res., 2009, 69, 5584-91.
135. Alvarez S. E.; Harikumar K. B.; Hait N. C.; Allegood J.; Strub G. M.; Kim E. Y.; Maceyka M.; Jiang H.; Luo C.; Kordula T. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature, 2010, 465, 1084-88.
136. Hait N.; Allegood J.; Maceyka M.; Strub G.; Harikumar K.; Singh S.; Luo C.; Marmorstein R.; Kordula T.; Milstien S. Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate. Science, 2009, 325, 1254-57.
137. Oi N.; Jeong C. H.; Nadas J.; Cho Y. Y.; Pugliese A.; Bode A. M.; Dong Z. Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A4 hydrolase. Cancer Res., 2010, 70, 9755-64.
138. Amaro R. E.; Schnaufer A.; Interthal H.; Hol W.; Stuart K. D.; McCammon J. A. Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 17278-83.
139. Amaro R. E.; Baron R.; McCammon J. A. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput. Aided Mol. Des., 2008, 22, 693-705.
140. Morris G. M.; Goodsell D. S.; Halliday R. S.; Huey R.; Hart W. E.; Belew R. K.; Olson A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-62. (Pubitemid 128590223)
141. Sherman W.; Day T.; Jacobson M. P.; Friesner R. A.; Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem., 2006, 49, 534-53. (Pubitemid 43157487)
142. Xie L.; Wang J.; Bourne P. E. In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. PLoS Comput. Biol., 2007, 3, e217.
143. Kinnings S. L.; Liu N.; Buchmeier N.; Tonge P. J.; Xie L.; Bourne P. E. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput. Biol., 2009, 5, e1000423.
144. Xie L.; Bourne P. E. Structure-based systems biology for analyzing off-target binding. Curr. Opin. Struct. Biol., 2011, 21, 189-99.
145. Cheng L. S.; Amaro R. E.; Xu D.; Li W. W.; Arzberger P. W.; McCammon J. A. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J. Med. Chem., 2008, 51, 3878-94. (Pubitemid 351956517)
146. Wolber G.; Seidel T.; Bendix F.; Langer T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today, 2008, 13, 23-29.
147. Jenkins J. L.; Bender A.; Davies J. W. In silico target fishing: Predicting biological targets from chemical structure. Drug Discov. Today, 2007, 3, 413-21. (Pubitemid 46158395)
148. Ekins S.; Mestres J.; Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br. J. Pharmacol., 2007, 152, 21-37. (Pubitemid 47339897)
149. Rognan D. Chemogenomic approaches to rational drug design. Br. J. Pharmacol., 2007, 152, 38-52. (Pubitemid 47339898)
150. Young D. W.; Bender A.; Hoyt J.; McWhinnie E.; Chirn G. W.; Tao C. Y.; Tallarico J. A.; Labow M.; Jenkins J. L.; Mitchison T. J. Integrating highcontent screening and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol., 2007, 4, 59-68. (Pubitemid 350273652)
151. Yildirim M. A.; Goh K. I.; Cusick M. E.; Barabsi A. L.; Vidal M. Drugtarget network. Nat. Biotechnol., 2007, 25, 1119-26.
152. Prathipati P.; Ma N. L.; Manjunatha U. H.; Bender A. Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. J. Proteome Res., 2009, 8, 2788-98.
153. Bender A.; Mikhailov D.; Glick M.; Scheiber J.; Davies J. W.; Cleaver S.; Marshall S.; Tallarico J. A.; Harrington E.; Cornella-Taracido I. Use of Ligand Based Models for Protein Domains To Predict Novel Molecular Targets and Applications To Triage Affinity Chromatography Data. J. Proteome Res., 2009, 8, 2575-85.
154. Muchmore S. W.; Debe D. A.; Metz J. T.; Brown S. P.; Martin Y. C.; Hajduk P. J. Application of belief theory to similarity data fusion for use in analog searching and lead hopping. J. Chem. Inf. model., 2008, 48, 941-48.
155. Keiser M. J.; Setola V.; Irwin J. J.; Laggner C.; Abbas A. I.; Hufeisen S. J.; Jensen N. H.; Kuijer M. B.; Matos R. C.; Tran T. B. Predicting new molecular targets for known drugs. Nature, 2009, 462, 175-81.
156. Yera E. R.; Cleves A. E.; Jain A. N. Chemical Structural Novelty: On-Targets and Off-Targets. J. Med. Chem., 2011, 54, 6771-85.
157. Kuhn M.; Campillos M.; Letunic I.; Jensen L. J.; Bork P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol., 2010, 6, 343.
158. Campillos M.; Kuhn M.; Gavin A. C.; Jensen L. J.; Bork P. Drug target identification using side-effect similarity. Science, 2008, 321, 263-66. (Pubitemid 351989100)
159. Zhao S.; Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS One, 2010, 5, e11764.
160. Yabuuchi H.; Niijima S.; Takematsu H.; Ida T.; Hirokawa T.; Hara T.; Ogawa T.; Minowa Y.; Tsujimoto G.; Okuno Y. Analysis of multiple compound-protein interactions reveals novel bioactive molecules. Mol. Syst. Biol., 2011, 7, 472.
161. Yizhak K.; Benyamini T.; Liebermeister W.; Ruppin E.; Shlomi T. Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model. Bioinformatics, 2010, 26, i255-i60.
162. Zhang C.; Frias M. A.; Mele A.; Ruggiu M.; Eom T.; Marney C. B.; Wang H.; Licatalosi D. D.; Fak J. J.; Darnell R. B. Integrative modeling defines the Nova splicing-regulatory network and its combinatorial controls. Science, 2010, 329, 439-43.
163. Dittrich M. T.; Klau G. W.; Rosenwald A.; Dandekar T.; Muller T. Identifying functional modules in protein-protein interaction networks: an integrated exact approach. Bioinformatics, 2008, 24, i223-i31.
164. Yosef N.; Ungar L.; Zalckvar E.; Kimchi A.; Kupiec M.; Ruppin E.; Sharan R. Toward accurate reconstruction of functional protein networks. Mol. Syst. Biol., 2009, 5, 248.
165. Ma H.; Goryanin I. Human metabolic network reconstruction and its impact on drug discovery and development. Drug Discov. Today, 2008, 13, 402-08.
166. Bottcher T.; Pitscheider M.; Sieber S. A. Natural products and their biological targets: proteomic and metabolomic labeling strategies. Angew. Chem. Int. Ed., 2010, 49, 2680-98.
167. Kitano H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov., 2007, 5, 202-10. (Pubitemid 46344624)
168. Dixon N.; Wong L. S.; Geerlings T. H.; Micklefield J. Cellular targets of natural products. Nat. Prod. Rep., 2007, 24, 1288-310. (Pubitemid 350161738)
169. Overington J. P.; Al-Lazikani B.; Hopkins A. L. How many drug targets are there? Nat. Rev. Drug Discov., 2006, 5, 993-96. (Pubitemid 44835126)
170. Nwaka S.; Hudson A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov., 2006, 5, 941-55. (Pubitemid 44660607)
171. Hopkins A. L. Network pharmacology. Nat. Biotechnol., 2007, 25, 1110-11. (Pubitemid 47538107)
172. Zhao J.; Jiang P.; Zhang W. Molecular networks for the study of TCM Pharmacology. Brief Bioinform., 2010, 11, 417-30.
173. Hopkins A. L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4, 682-90.
174. Jia J.; Zhu F.; Ma X.; Cao Z. W.; Li Y. X.; Chen Y. Z. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov., 2009, 8, 111-28.